Zeydovio (glepaglutide)

Where it stands

Zeydovio (glepaglutide), from Zealand Pharma A/S, received a CHMP positive opinion on 2026-09-17 for the treatment of adults with Short Bowel Syndrome in the EU. The records list its status as 'Opinion', and no approval date is recorded. That means the European Commission (EC) has not yet issued a decision, at least as far as the records show.

A CHMP opinion is a scientific recommendation from the EMA's committee. It is not a marketing authorisation. The authorisation becomes legally effective in all EU member states only when the EC adopts its decision. The records give an estimated EC decision date of 2026-11-23, calculated as the opinion date plus 67 days, the standard Commission decision period. This is an estimate, not an official date, and the actual timing could differ.

Regulatory pathway and designations

The records show no designations for this product. No orphan, PRIME, accelerated assessment or conditional approval status is recorded. I cannot say whether any applied during development or review, only that none appear in the data provided.

The records do not specify the type of procedure or the legal basis of the application. In general, a positive CHMP opinion under the centralised procedure is followed by an EC decision, usually within about 67 days. This is the basis for the estimated date. The opinion covers a single indication, treatment of adults with Short Bowel Syndrome. Any further conditions attached to the authorisation are not recorded.

Safety and pharmacovigilance

The records contain no information on safety findings, adverse events, risk management plan content, additional monitoring or post-authorisation commitments for Zeydovio. I will not infer a safety profile from the active substance or the therapeutic class.

Readers should consult the CHMP assessment report, the summary of product characteristics and the EPAR once published. These will set out the approved safety information, any risk minimisation measures and any post-authorisation obligations.

What to watch

The main near-term event is the EC decision, estimated for 2026-11-23. This is a projection based on the standard timeline and not a confirmed date. A decision would move the product from 'Opinion' to an approved status with a recorded approval date.

Beyond that, the final product information, including the wording of the indication and any conditions, will become clear once the EC decision and the associated EMA documents are published. The records contain nothing on launch timing, pricing, reimbursement or national access, so none of these can be assessed here.